X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MERCK LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA MERCK LTD ASTRAZENECA PHARMA/
MERCK LTD
 
P/E (TTM) x 157.6 52.6 299.8% View Chart
P/BV x 24.5 7.9 308.2% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   MERCK LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MERCK LTD
Dec-16
ASTRAZENECA PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,2851,060 121.2%   
Low Rs634623 101.8%   
Sales per share (Unadj.) Rs189.6632.4 30.0%  
Earnings per share (Unadj.) Rs-0.245.7 -0.4%  
Cash flow per share (Unadj.) Rs3.862.3 6.2%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs68.6388.8 17.7%  
Shares outstanding (eoy) m25.0016.60 150.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.3 380.4%   
Avg P/E ratio x-4,712.718.4 -25,602.9%  
P/CF ratio (eoy) x249.613.5 1,848.2%  
Price / Book Value ratio x14.02.2 645.9%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m23,98813,969 171.7%   
No. of employees `0001.61.6 98.5%   
Total wages/salary Rs m1,6051,487 107.9%   
Avg. sales/employee Rs Th3,040.26,631.9 45.8%   
Avg. wages/employee Rs Th1,029.2939.2 109.6%   
Avg. net profit/employee Rs Th-3.3479.4 -0.7%   
INCOME DATA
Net Sales Rs m4,74010,498 45.1%  
Other income Rs m92242 38.0%   
Total revenues Rs m4,83210,741 45.0%   
Gross profit Rs m-1301,135 -11.4%  
Depreciation Rs m101276 36.7%   
Interest Rs m00-   
Profit before tax Rs m-1391,102 -12.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5343 1.5%   
Profit after tax Rs m-5759 -0.7%  
Gross profit margin %-2.710.8 -25.3%  
Effective tax rate %-3.731.1 -11.8%   
Net profit margin %-0.17.2 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,7266,410 42.5%   
Current liabilities Rs m2,4358,828 27.6%   
Net working cap to sales %6.1-23.0 -26.7%  
Current ratio x1.10.7 154.2%  
Inventory Days Days7458 127.9%  
Debtors Days Days4138 106.2%  
Net fixed assets Rs m1,0351,406 73.6%   
Share capital Rs m50166 30.1%   
"Free" reserves Rs m9426,286 15.0%   
Net worth Rs m1,7166,455 26.6%   
Long term debt Rs m00-   
Total assets Rs m4,1568,828 47.1%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.2 95.9%   
Return on assets %-0.18.6 -1.4%  
Return on equity %-0.311.8 -2.5%  
Return on capital %017.1 0.0%  
Exports to sales %5.78.3 68.8%   
Imports to sales %6.521.0 30.7%   
Exports (fob) Rs m270869 31.1%   
Imports (cif) Rs m3062,209 13.9%   
Fx inflow Rs m375959 39.1%   
Fx outflow Rs m4702,612 18.0%   
Net fx Rs m-96-1,653 5.8%   
CASH FLOW
From Operations Rs m-81,070 -0.8%  
From Investments Rs m-146-750 19.4%  
From Financial Activity Rs m862-150 -575.6%  
Net Cashflow Rs m709171 414.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 15.7 1.0 1,570.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   12,856 28,591 45.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS